

the importance of minimizing costs for repetitive, return visits to obtain respondent cooperation, NIDA is considering the provision of a reasonable cost incentive to reimburse respondents for their time.

REQUEST FOR COMMENTS: Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Susan David, Project Officer; Division of Epidemiology and Prevention Research, National Institutes

on Drug Abuse, Room 9A54, 5600 Fishers Lane, Rockville, MD 20857; or call non-toll-free number (301) 443-6543; or fax to (301) 443-2636; or e-mail your request, including your address, to: Sd69t@nih.gov.

COMMENTS DUE DATE: Comments regarding this information collection are best assured of having their full effect if received by January 29, 1999.

Dated: November 19, 1998.

Laura Rosenthal,
Executive Officer, NIDA.
[FR Doc. 98-31728 Filed 11-27-98; 8:45 am]
BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Proposed Data Collection; Comment Request; Survey of Colorectal Cancer Screening Practices in Health Care Organizations

SUMMARY: In compliance with the provisions of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comments on proposed data collection projects, the National Institutes of Health (NIH), National Cancer Institute (NCI) will publish periodic summaries of proposed projects to be submitted to the Office of

Management and Budget for review and approval.

PROPOSED COLLECTION: *Title:* Survey of Colorectal Cancer Screening Practices in Health Care Organizations. *Type of Information Collection Request:* New. *Need and Use of Information Collection:* This study will measure primary care and specialty physicians' knowledge, attitudes, and practice patterns related to colorectal cancer screening and diagnostic follow-up. This study also will assess guidelines, policies, and programs to provide or promote colorectal cancer screening within health plans. The purpose of this study is to obtain current, nationally representative data on the physician and health system factors that may influence the use of colorectal cancer screening and diagnostic follow-up for suspected colorectal cancer in community practice. Three questionnaires will be administered by mail, telephone, facsimile, or Internet using national samples of physicians and health plans. Study participants will select their preferred response mode. Study participants will be primary care and speciality physicians with active licenses to practice medicine in the U.S., and the medical directors of health plans listed by the American Association of Health Plans. Burden estimates are as follows:

Questionnaire	Estimated # respondents	# responses per respondent	Average burden hours per response	Estimated total annual burden hours
Primare care physician	1,810	1	0.250	452
Speciality physician	1,544	1	0.333	514
Health plan	453	1	0.333	151
Total:				1,117

REQUEST FOR COMMENTS: Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (a) whether the proposed collection of information is necessary for the performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

FOR FURTHER INFORMATION CONTACT: Send comments to Carrie N. Klabunde,

Ph.D., Epidemiologist, National Cancer Institute, EPN 313, 6130 Executive Boulevard, MSC 7344, Bethesda, Maryland 20892-7344, telephone 301-402-3362.

COMMENTS DUE DATE: Comments regarding this information collection are best assured of having their full effect if received by January 29, 1999.

Dated: November 19, 1998.

Reesa Nichols,
OMB Project Clearance Liaison.
[FR Doc. 98-31729 Filed 11-27-98; 8:45 am]
BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Licensing Opportunity and/or Cooperative Research and Development Agreement ("CRADA") Opportunity: Drug And Method For The Therapeutic Treatment of Lymphomas And Leukemias

AGENCY: National Institutes of Health, PHS, DHHS.

ACTION: Notice.

SUMMARY: The NIH is seeking Licensee(s) and/or a Cooperative Research and Development Agreement ("CRADA") to further develop, evaluate, and commercialize a recombinant immunotoxin, termed RFB4(dsFv)-PE38